

REMARKS

Claim Amendments

After entry of this amendment, claims 6-10 and 22 are pending. Claims 6, 7 and 10 have been amended.

Sequence Listing

Applicants request entry of the fourth substitute sequence listing in accordance with 37 C.F.R. §§ 1.821-1.825. This Substitute Sequence Listing is submitted to replace the "SEQUENCE LISTING" submitted on August 21, 2007, which contained an improper description of the amino acid, which connects Methionine and Valine, at positions 2 and 3 of SEQ ID NO:94. In SEQ ID NO:99, the first amino acid was omitted. The Sequence Listing submitted herewith replaces "statine, aha(cyclohexylmethylstatine) or phenylstatine" with "statine" in SEQ ID NO:94 and adds Valine at position 1 of SEQ ID NO:99.

This amendment includes a sequence listing in computer readable form (CRF), and a paper copy of the sequence information which has been printed from the CRF sequence listing. The information contained in the CRF sequence listing was prepared using the software program "PatentIn 3.3" and is identical to the paper copy submitted enclosed in the Appendix. This amendment contains no new matter.

Applicants now address the Examiner's remarks on the claim objections and rejections using the paragraph numbering of the office action.

5. The Examiner's remark regarding SEQ ID NO:94 is rendered moot by the submission of the fourth substitute sequence listing. The amino acid sequence of SEQ ID NO:94 is consistent with the description, as the description indicates that Methionine and Valine at positions 2 and 3 are linked via statine molecule. Examiner pointed out that SEQ ID NO:96 has Leu at position 3 in the Sequence Listing, while SEQ ID NO:96 in claim 7 has n-Leu at position 3. In the Specification, n-Leu indicates normal leucine (see page 79, lines 8-9), therefore it is

correctly identified as Leu in the Sequence Listing. For more clarity, claim 7 has been amended; in SEQ ID NO:96 n-Leu has been replaced with Leu at position 3.

Claim Objection

6-7. Claims 6-10 have been amended according to the Examiner's suggestions.

Claim Rejections - 35 USC § 112

8-9. In the light of the fourth substitute sequence listing, the Examiner's remarks regarding SEQ ID NO:99 are rendered moot, as the description indicates that SEQ ID NO:99 has seven amino acids and Valine is at position 1. As to SEQ ID NOs:94, and 96 the Examiner's remark is rendered moot as discussed above.

10. Claim 10 has been amended to recite the correct sequence ID number (SEQ ID NO:100).

11. Claim 6 has been amended as suggested mooted the rejection with respect to dependent claim 22.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 415-576-0300
Attachments
JOL:kew
61210970 v1